Manufacturing License Granted to Alvotech for Biopharma Facility
Specialist biopharmaceutical company, Alvotech, has announced receipt of a manufacturing license from the Icelandic Medicines Agency, applying to its biopharmaceutical facility based in Reykjavik, Iceland.
Specialist biopharmaceutical company, Alvotech, has announced receipt of a manufacturing license from the Icelandic Medicines Agency, applying to its biopharmaceutical facility based in Reykjavik, Iceland.
Founded in 2013, Alvotech is focused on the development and manufacture of high quality biosimilar products. The Icelandic facility, which is 13,000 m2in size, is located within the science park of the University of Iceland and dedicated to developing and manufacturing the company’s broad biosimilar portfolio.
Through this manufacturing license, granted by the Icelandic Medicines Agency in consultation with the Irish Health Products Regulatory Authority, the company has confirmed its compliance with the good manufacturing practice (GMP) directive 2003/94/EC guidelines and principles.
“The issuance of the manufacturing licence from the Icelandic Medicines Agency is another important milestone on our journey to providing patients with more easily accessible and affordable high-quality biopharmaceuticals,” explained the company’s CEO, Rojkjaer Rasmus, in a press release. “It’s the product of a lot of hard work by the Alvotech team and reflects our commitment to becoming a leading player in the biosimilar industry. With a full-scale best-in-class manufacturing capability, we are well positioned to take on opportunities in the global biosimilar market.”
Source: Alvotech
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.
Teva and Samsung Bioepis Launch Biosimilar Eculizumab in US Market
April 17th 2025Eculizumab-aagh (EPYSQLI) is now available in the US to treat patients living with difficult-to-treat rare diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis.
